Bringing Clarity to Clinical Decisions in Thoracic Cancers: Translating Data Into Practice
  • CME

Get an expert’s recommendations on optimal management of patients newly diagnosed with thoracic malignancies, including metastatic adenocarcinoma with an uncommon EGFR mutation, squamous NSCLC with low PD-L1 levels, highly symptomatic metastatic adenocarcinoma with high PD-L1 levels, and unresectable malignant pleural mesothelioma.
Anne S. Tsao, MD
Program Director
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: January 7, 2019 Expiration: January 6, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Choose optimal first-line therapy for patients with EGFR-positive NSCLC considering the available clinical data and available treatment options
  • Select treatment for patients with squamous NSCLC, in the first-line setting and beyond
  • Sequence therapies for maximum benefit in patients with EGFR-positive NSCLC
  • Address emerging evidence on the efficacy of various antiangiogenic agents in NSCLC
  • Evaluate the clinical data on available and promising investigational agents for patients with NSCLC and unresectable MPM


Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from
Boehringer Ingelheim

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Anne S. Tsao, MD

Division of Cancer Medicine
Department of Thoracic/Head and Neck Medical Oncology
Department of Mesothelioma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

Anne S. Tsao, MD, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, Novella Clinical, and TRM Oncology; funds for research support from Genentech, MedImmune, and Millennium; and fees for non-CME/CE services from TRM Oncology.


Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Joy Curzio

Editorial Contributor

Joy Curzio has disclosed that her spouse/partner holds ownership interests with Advaxis.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with NSCLC and MPM.


The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with NSCLC and MPM.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 07, 2019, through January 06, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Results from the phase I/II study of TAK-788 in previously treated NSCLC with EGFR exon 20 insertions, from ASCO 2019 as reported by CCO

Released: June 11, 2019

Early phase study results of iberdomide plus dexamethasone in patients with R/R MM as reported by CCO from ASCO 2019

Released: June 7, 2019

TRANSCEND CLL 004: high activity, manageable toxicity with liso-cel CAR T-cell therapy in R/R CLL/SLL, as reported by CCO from ASCO 2019

Released: June 7, 2019

Solange Peters, MD, PhD, discusses key lung cancer presentations from the 2019 European Lung Cancer Congress (ELCC 2019) from Clinical Care Options.

Solange Peters, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: June 6, 2019 Expiration: June 5, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?